At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 60 enrolled
Drug / intervention
Ramucirumabbiological
Likely dose
Ramucirumab 8 milligramsfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2, Non-randomized, Open-label, Multicenter Study of IMC-1121B in the Treatment of Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma
In Brief
A Phase 2 clinical trial evaluating Ramucirumab for Ovarian Cancer and 2 related conditions. Completed, enrolled 60 participants across 13 sites in 2 countries.
Detailed Summary
The purpose of this study is to determine if ramucirumab given as monotherapy is effective in the treatment of Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited Kingdom, United States
Collaborators--
Timeline
Phase 2CompletedFinished
2009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJul 2008
Enrollment StartAug 2008
Primary CompletionMay 2012
Study CompletionAug 2015
TodayJul 2026
First PostedJul 23, 2008
Enrollment StartAug 1, 2008
Primary CompletionMay 1, 2012
Study CompletionAug 1, 2015
TodayJul 2, 2026
Enrollment to primary: 3.8 yearsPosted 17.9 years ago
Interventions
Ramucirumabbiological
Participants will receive ramucirumab at 8 milligrams/kilogram (mg/kg) administered over 1 hour every other week (every 14 days). Treatment will continue until there is evidence of disease progression, intolerable toxicity, or other withdrawal criteria are met.